secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001764013-24-000162
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial
--------------------------------------------------------------------------------

- High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.
- Lower-dose batoclimab (340 mg) yielded 68% response and 36% ATD-free response; 70%+ IgG reduction linked to nearly 3x higher ATD-free response.
- FDA IND cleared; pivotal trial of IMVT-1402 in Graves' Disease expected to initiate by December 31, 2024.
- Real-world claims data indicate 25–30% of GD patients per year are uncontrolled on ATDs with limited existing therapeutic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000162/0001764013-24-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000162/imvt-20240909.htm
  HTML page:      https://secwatch.observer/filing/0001764013-24-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer